FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2 Tyrosine Kinase Domain Activating Mutations By Ogkologos - August 29, 2025 625 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Investing in volunteers since 2002: The tale of time July 11, 2022 FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection October 2, 2025 Can a Biopsy Make My Cancer Spread? March 18, 2021 Cancer in My Community: Overcoming Inequities in Care in Argentina January 3, 2023 Load more HOT NEWS New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukaemia with... Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows Professor Eithne Costello: On the road to early detection
